Cogent Biosciences
company
About
Cogent Biosciences is a biopharmaceutical company that develops therapies for solid cancer tumors.
- 101 - 250
Highlights
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $65M
- Industries
- Biotechnology,Health Care,Medical,Therapeutics
- Founded date
- Jan 1, 2014
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Cogent Biosciences uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its Antibody-Coupled T-cell Receptor technology, is expected to enter Phase I clinical testing in the coming months to assess safety and efficacy.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$65M
Cogent Biosciences has raised a total of
$65M
in funding over 2 rounds. Their latest funding was raised on
Jun 11, 2015 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 11, 2015 | Series B | $65M | 1 | — | — | Detail |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
